(Q46657407)

English

p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.

scientific article published on 7 April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Kenneth C. Anderson

19

object named as

Kenneth C Anderson

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Tanyel Kiziltepe

9

object named as

Tanyel Kiziltepe

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Pierfrancesco Tassone

12

object named as

Pierfrancesco Tassone

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Kenji Ishitsuka

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Teru Hideshima

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Paola Neri

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Sonia Vallet

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Norihiko Shiraishi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Yutaka Okawa

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Zhenxin Shen

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Noopur Raje

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Dharminder Chauhan

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Nikhil Munshi

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Robert M Campbell

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Alfonso De Dios

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Chuan Shih

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

James J Starling

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Kazuo Tamura

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

0 references

publication date

7 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

141

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

598-606

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18397345%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Transcriptional and posttranscriptional roles for p38 mitogen-activated protein kinase in upregulation of TNF-alpha expression by deoxynivalenol (vomitoxin).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Superinduction of IL-6 by cycloheximide is associated with mRNA stabilization and sustained activation of p38 map kinase and NF-kappaB in cultured caco-2 cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Advances in biology of multiple myeloma: clinical applications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Identification and validation of novel therapeutic targets for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Nitric oxide post-transcriptionally up-regulates LPS-induced IL-8 expression through p38 MAPK activation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Macrophage inflammatory protein-1

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Bortezomib inhibits human osteoclastogenesis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

A clinically relevant SCID-hu in vivo model of human multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Interleukin-6 modulates production of T lymphocyte–derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07044.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46657407&oldid=2032509719"